Rapport Therapeutics, Inc. Common Stock • RAPP

Capital at risk.

About Rapport Therapeutics, Inc. Common Stock
Ticker
info
RAPP
Trading on
info
NASDAQ
ISIN
info
US75383L1026
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Abraham N. Ceesay M.B.A.
Headquarters
info
1325 Boylston Street, Boston, MA, United States, 02215
Employees
info
69
Website
info
rapportrx.com
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$414M
P/E ratio
info
-
EPS
info
-$3.78
Dividend Yield
info
0.00%
Beta
info
-
Forward P/E ratio
info
0
EBIDTA
info
$-82.2M
Ex dividend date
info
-
Price & volume
Market cap
info
$414M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
1.35
Earnings
EPS
info
-$3.78
EPS estimate (current quarter)
info
-$0.57
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-82.2M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
-
52-week High
info
$29.74
52-week Low
info
$6.43
50-day moving average
info
$10.08
200-day moving average
info
$17.65
Short ratio
info
8.94
Short %
info
7.28%
Management effectiveness
ROE (TTM)
info
35.09%
ROA (TTM)
info
22.07%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
36.5M
Float
info
14.9M
Insiders %
info
6.59%
Institutions %
info
101.96%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 4 analysts.

Average price target

info
$35.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$1.70
-$0.68
150.00%
Q2 • 24Beat
-$0.50
-$0.52
3.85%
Q3 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-17.5M
∞%
Q3 • 24
$0M
$-20M
∞%
Q4 • 24
NaN%
13.93%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$331M
$8M
2.42%
Q3 • 24
$315M
$9.5M
3.02%
Q4 • 24
4.90%
18.38%
24.47%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-16.4M
$-53M
$-1.4M
$-16.6M
Q3 • 24
$-14.4M
$31.9M
$0M
$-14.7M
Q4 • 24
12.00%
160.20%
100.50%
11.37%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Rapport Therapeutics, Inc. Common Stock share?
Collapse

Rapport Therapeutics, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Rapport Therapeutics, Inc. Common Stock have?
Collapse

Rapport Therapeutics, Inc. Common Stock currently has 36.5M shares.

Does Rapport Therapeutics, Inc. Common Stock pay dividends?
Collapse

No, Rapport Therapeutics, Inc. Common Stock doesn't pay dividends.

What is Rapport Therapeutics, Inc. Common Stock 52 week high?
Collapse

Rapport Therapeutics, Inc. Common Stock 52 week high is $29.74.

What is Rapport Therapeutics, Inc. Common Stock 52 week low?
Collapse

Rapport Therapeutics, Inc. Common Stock 52 week low is $6.43.

What is the 200-day moving average of Rapport Therapeutics, Inc. Common Stock?
Collapse

Rapport Therapeutics, Inc. Common Stock 200-day moving average is $17.65.

Who is Rapport Therapeutics, Inc. Common Stock CEO?
Collapse

The CEO of Rapport Therapeutics, Inc. Common Stock is Abraham N. Ceesay M.B.A..

How many employees Rapport Therapeutics, Inc. Common Stock has?
Collapse

Rapport Therapeutics, Inc. Common Stock has 69 employees.

What is the market cap of Rapport Therapeutics, Inc. Common Stock?
Collapse

The market cap of Rapport Therapeutics, Inc. Common Stock is $414M.

What is the P/E of Rapport Therapeutics, Inc. Common Stock?
Collapse

The current P/E of Rapport Therapeutics, Inc. Common Stock is null.

What is the EPS of Rapport Therapeutics, Inc. Common Stock?
Collapse

The EPS of Rapport Therapeutics, Inc. Common Stock is -$3.78.

What is the PEG Ratio of Rapport Therapeutics, Inc. Common Stock?
Collapse

The PEG Ratio of Rapport Therapeutics, Inc. Common Stock is null.

What do analysts say about Rapport Therapeutics, Inc. Common Stock?
Collapse

According to the analysts Rapport Therapeutics, Inc. Common Stock is considered a buy.